口咽癌机器人术后辅助治疗:国家实践与指南标准的比较
该研究利用美国国家癌症数据库分析早期至中期口咽鳞癌机器人术后放疗的实际使用频率,并评估在存在明确辅助治疗指征时指南依从性。结果显示约三分之二患者术后接受放疗,但五分之一的辅助放疗指征患者和三分之一的辅助化疗指征患者未接受推荐治疗。
要点
- 早期至中期口咽癌机器人术后约2/3患者接受放疗。
- 有辅助放疗指征者中约1/5未接受推荐放疗。
- 有辅助化疗指征者中约1/3未接受推荐化疗。
核心结论
- 早期至中期口咽鳞癌机器人术后放疗需求比例高,但部分有辅助治疗指征的患者未接受推荐治疗。
研究设计与样本
- 基于美国国家癌症数据库的回顾性分析,纳入cT1-3cN0-2cM0口咽鳞癌机器人手术患者。
主要发现
- 约三分之二患者在接受机器人手术后接受了放疗。
- 有辅助放疗指征的患者中约五分之一未接受推荐放疗。
- 有辅助化疗指征的患者中约三分之一未接受推荐化疗。
临床怎么用
- 临床应对照指南评估机器人术后辅助治疗指征,减少有指征但未治疗的情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent historical management of oropharyngeal squamous cell carcinoma typically includes radiotherapy with/without chemotherapy. Novel surgical techniques such as robotic surgery have made primary surgery more frequent; however, postoperative radiotherapy may be recommended. We aimed to assess adherence to guidelines for postoperative therapy following robotic surgery. METHODS: Using the National Cancer Database, we analyzed the frequency of radiotherapy following robotic surgery for cT1-3cN0-2cM0 squamous cell carcinoma of the oropharynx, specifically in the presence of widely accepted indications for postoperative radiotherapy and/or chemotherapy. RESULTS: Approximately two-thirds of patients received radiotherapy after robotic surgery for early-intermediate stage oropharyngeal cancer. One in five patients with an indication for adjuvant radiotherapy and 1/3 with an indication for adjuvant chemotherapy did not receive recommended adjuvant therapy. CONCLUSIONS: A high proportion of patients require radiotherapy after robotic surgery for early-intermediate stage oropharyngeal cancer. Patients with an indication for further adjuvant therapy commonly do not receive it.
引用
- Bates JE, Hitchcock KE, Mendenhall WM, et al. Comparing national practice versus standard guidelines for the use of adjuvant treatment following robotic surgery for oropharyngeal squamous cell carcinoma. Head Neck. 2020. PMID: 32476219. doi:10.1002/hed.26311
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。